We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $15.84, marking a -2.64% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.56%. Meanwhile, the Dow experienced a rise of 0.26%, and the technology-dominated Nasdaq saw an increase of 0.78%.
Shares of the company have depreciated by 46.6% over the course of the past month, underperforming the Medical sector's gain of 0.65%, and the S&P 500's loss of 1.27%.
Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company plans to announce its earnings on February 23, 2026. The company is predicted to post an EPS of $0.02, indicating a 81.82% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $619.19 million, reflecting a 28.69% rise from the equivalent quarter last year.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.48 per share and revenue of $2.35 billion. These results would represent year-over-year changes of +77.78% and +59.07%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.09% lower. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #4 (Sell).
Digging into valuation, Hims & Hers Health, Inc. currently has a Forward P/E ratio of 29.79. This denotes a premium relative to the industry average Forward P/E of 21.61.
Also, we should mention that HIMS has a PEG ratio of 3.04. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical Info Systems industry had an average PEG ratio of 1.28.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 134, putting it in the bottom 46% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $15.84, marking a -2.64% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.56%. Meanwhile, the Dow experienced a rise of 0.26%, and the technology-dominated Nasdaq saw an increase of 0.78%.
Shares of the company have depreciated by 46.6% over the course of the past month, underperforming the Medical sector's gain of 0.65%, and the S&P 500's loss of 1.27%.
Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company plans to announce its earnings on February 23, 2026. The company is predicted to post an EPS of $0.02, indicating a 81.82% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $619.19 million, reflecting a 28.69% rise from the equivalent quarter last year.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.48 per share and revenue of $2.35 billion. These results would represent year-over-year changes of +77.78% and +59.07%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.09% lower. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #4 (Sell).
Digging into valuation, Hims & Hers Health, Inc. currently has a Forward P/E ratio of 29.79. This denotes a premium relative to the industry average Forward P/E of 21.61.
Also, we should mention that HIMS has a PEG ratio of 3.04. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical Info Systems industry had an average PEG ratio of 1.28.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 134, putting it in the bottom 46% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.